Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFMO and Bicalutamide in Localized Prostate Cancer
NCT00086736Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Nov 2001
- Primary completion
- Nov 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eflornithine in prostate cancer (PCa) (4 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Levels of polyamine spermine, polyamine putrescine, and spermidine. Started Nov 2001; status: completed.
02
Drugs
eflornithine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00086736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086736.